Article
TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes.
International journal of cancer - 15 Oct 2016
Lazarian Gregory, Tausch Eugen, Eclache Virginie, Sebaa Amel, Bianchi Vincent, Letestu Remi, Collon Jean-Francois, Lefebvre Valerie, Gardano Laura, Varin-Blank Nadine, Soussi Thierry, Stilgenbauer Stephen, Cymbalista Florence, Baran-Marszak Fanny
Abstract excerpt
TP53 abnormalities lead to resistance to purine analogues and are found in over 40% of patients with refractory chronic lymphocytic leukemia (CLL). At diagnosis, no more than 5% of patients carry the 17p deletion, most cases harbour mutations within the other TP53 allele. The incidence of a TP53 mutation as the only alteration is approximately 5%, but this depends on the sensitivity of the technique. Recently,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.